Adhera Therapeutics, Inc. ATRX

ATRX Company Overview

Adhera Therapeutics, Inc. (formerly Marina Biotech, Inc.) is a U.S.-based biotechnology company focused on the development of therapeutics targeting neurological, neuropsychiatric, and addiction-related disorders. Public disclosures and historical regulatory filings indicate that the company’s strategy centered on repurposing and developing compounds intended to address conditions with significant unmet medical needs, including Parkinson’s disease-related dyskinesia and substance use disorders. The company has traded under the ticker symbol ATRX and has historically operated within the broader biotechnology and specialty pharmaceutical industries.

The company’s principal development efforts were associated with adenosine-regulating compounds, including clinical-stage therapeutic candidates acquired through strategic transactions. Historical company materials and SEC disclosures indicate that Adhera Therapeutics evolved from an RNAi-focused biotechnology platform under the Marina Biotech name into a neuroscience-oriented therapeutics developer after a corporate restructuring and rebranding effort. Publicly available information regarding recent commercial operations, active revenue generation, or late-stage commercialization remains limited, and some operational details are inconclusive based on available public sources.